Rivaroxaban Treatment for Heparin-Induced Thrombocytopenia: A Case Report and a Review of the Current Experience
Heparin-induced thrombocytopenia is a life-threatening complication of exposure to heparin. Heparin-induced thrombocytopenia results from an autoantibody directed against platelet factor 4 in complex with heparin. Heparin-induced thrombocytopenia is traditionally treated with bivalirudin, argatroban...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Case Reports in Hematology |
| Online Access: | http://dx.doi.org/10.1155/2020/8885256 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832553457762959360 |
|---|---|
| author | Mohamed Aon Omar Al-Shammari |
| author_facet | Mohamed Aon Omar Al-Shammari |
| author_sort | Mohamed Aon |
| collection | DOAJ |
| description | Heparin-induced thrombocytopenia is a life-threatening complication of exposure to heparin. Heparin-induced thrombocytopenia results from an autoantibody directed against platelet factor 4 in complex with heparin. Heparin-induced thrombocytopenia is traditionally treated with bivalirudin, argatroban, danaparoid, or fondaparinux. Recently, direct oral anticoagulants administration to treat heparin-induced thrombocytopenia has been reported. Direct oral anticoagulants do not cause platelet activation in the presence of heparin-platelet factor 4 antibodies, nor do they provoke autoantibody production. Direct oral anticoagulants offer advantages such as consistent and predictable anticoagulation, oral administration with good patient compliance, and a good safety profile. We report a case of heparin-induced thrombocytopenia with deep venous thrombosis successfully treated with rivaroxaban and review the current experience with rivaroxaban for the treatment of heparin-induced thrombocytopenia. |
| format | Article |
| id | doaj-art-3f4c88df6f3a4703a8bc58a5cbed52d7 |
| institution | Kabale University |
| issn | 2090-6560 2090-6579 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Hematology |
| spelling | doaj-art-3f4c88df6f3a4703a8bc58a5cbed52d72025-02-03T05:53:54ZengWileyCase Reports in Hematology2090-65602090-65792020-01-01202010.1155/2020/88852568885256Rivaroxaban Treatment for Heparin-Induced Thrombocytopenia: A Case Report and a Review of the Current ExperienceMohamed Aon0Omar Al-Shammari1Department of Medicine, Jahra Hospital, Ministry of Health (HOM), Jahra city, KuwaitDepartment of Medicine, Jahra Hospital, Ministry of Health (HOM), Jahra city, KuwaitHeparin-induced thrombocytopenia is a life-threatening complication of exposure to heparin. Heparin-induced thrombocytopenia results from an autoantibody directed against platelet factor 4 in complex with heparin. Heparin-induced thrombocytopenia is traditionally treated with bivalirudin, argatroban, danaparoid, or fondaparinux. Recently, direct oral anticoagulants administration to treat heparin-induced thrombocytopenia has been reported. Direct oral anticoagulants do not cause platelet activation in the presence of heparin-platelet factor 4 antibodies, nor do they provoke autoantibody production. Direct oral anticoagulants offer advantages such as consistent and predictable anticoagulation, oral administration with good patient compliance, and a good safety profile. We report a case of heparin-induced thrombocytopenia with deep venous thrombosis successfully treated with rivaroxaban and review the current experience with rivaroxaban for the treatment of heparin-induced thrombocytopenia.http://dx.doi.org/10.1155/2020/8885256 |
| spellingShingle | Mohamed Aon Omar Al-Shammari Rivaroxaban Treatment for Heparin-Induced Thrombocytopenia: A Case Report and a Review of the Current Experience Case Reports in Hematology |
| title | Rivaroxaban Treatment for Heparin-Induced Thrombocytopenia: A Case Report and a Review of the Current Experience |
| title_full | Rivaroxaban Treatment for Heparin-Induced Thrombocytopenia: A Case Report and a Review of the Current Experience |
| title_fullStr | Rivaroxaban Treatment for Heparin-Induced Thrombocytopenia: A Case Report and a Review of the Current Experience |
| title_full_unstemmed | Rivaroxaban Treatment for Heparin-Induced Thrombocytopenia: A Case Report and a Review of the Current Experience |
| title_short | Rivaroxaban Treatment for Heparin-Induced Thrombocytopenia: A Case Report and a Review of the Current Experience |
| title_sort | rivaroxaban treatment for heparin induced thrombocytopenia a case report and a review of the current experience |
| url | http://dx.doi.org/10.1155/2020/8885256 |
| work_keys_str_mv | AT mohamedaon rivaroxabantreatmentforheparininducedthrombocytopeniaacasereportandareviewofthecurrentexperience AT omaralshammari rivaroxabantreatmentforheparininducedthrombocytopeniaacasereportandareviewofthecurrentexperience |